LIVIVO - Search results -

Search results

Result 1 - 10 of total 17

Search options

Article ; Online: Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.

Atienza-Mateo, Belén / Fernández-Díaz, Carlos / Vicente-Rabaneda, Esther F / Melero-González, Rafael B / Ortiz-Sanjuán, Francisco / Casafont-Solé, Ivette / Rodríguez-García, Sebastián C / Ferraz-Amaro, Iván / Castañeda, Santos / Blanco, Ricardo

European journal of internal medicine

2023 Volume 119, Page(s) 118–124

Abstract: Objective: To compare the effectiveness of abatacept (ABA) in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) according to the radiological patterns of usual (UIP) or non-specific interstitial pneumonia (NSIP).: Methods: From an ... ...

Abstract	Objective: To compare the effectiveness of abatacept (ABA) in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) according to the radiological patterns of usual (UIP) or non-specific interstitial pneumonia (NSIP). Methods: From an observational longitudinal multicentre study of 263 RA-ILD patients treated with ABA, those with UIP or NSIP were selected. Lung function, chest high resolution computerised tomography (HRCT) and dyspnoea were recorded and compared in both groups from baseline to the end of follow-up (progression definitions: improvement or worsening >10% of FVC or DLCO, changes in HRCT extension and 1-point change in the mMRC scale, respectively). Differences between final and baseline visits were calculated as the average difference (95% CI) through mixed effects models regression. Results: We studied 190 patients with UIP (n=106) and NSIP (n=84). General features were similar in both groups except for older age, positive rheumatoid factor, and previous sulfasalazine therapy, which were more frequent in patients with UIP. ILD duration up to ABA initiation was relatively short: median 16 [4-50] and 11 [2-36] months (p=0.36) in UIP and NSIP, respectively. Mean baseline FVC and DLCO were 82% and 63% in UIP and 89% and 65% in NSIP, respectively. Both parameters remained stable during 24 months with ABA. HRCT lesions and dyspnoea improved/stabilized in 73.1% and 90.5% and 72.9% and 94.6% of UIP and NSIP patterns, respectively. Conclusion: ABA seems equally effective in stabilizing dyspnoea, lung function and radiological impairment in both UIP and NSIP patterns of RA-ILD. Early administration of ABA may prevent RA-ILD progression, regardless of the radiological pattern.
MeSH term(s)	Humans ; Abatacept/therapeutic use ; Lung Diseases, Interstitial/diagnostic imaging ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/etiology ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Tomography, X-Ray Computed ; Dyspnea/complications ; Retrospective Studies
Chemical Substances	Abatacept (7D0YB67S97)
Language	English
Publishing date	2023-09-04
Publishing country	Netherlands
Document type	Multicenter Study ; Journal Article
ZDB-ID	1038679-8
ISSN	1879-0828 ; 0953-6205
ISSN (online)	1879-0828
ISSN	0953-6205
DOI	10.1016/j.ejim.2023.08.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2608: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Visual manifestations in giant cell arteritis: identification of risk factors from the ARTESER Registry.

Molina-Collada, Juan / Domínguez-Álvaro, Marta / Melero-González, Rafael B / Fernández-Fernández, Elisa / Silva-Díaz, Maite / Valero, Jesús Alejandro / González, Ismael / Martín, Julio Sánchez / Narváez, Javier / Calvo, Itziar / Mendizábal, Javier / Alcázar, Lydia Abasolo / Loricera, Javier / Roman, Alberto Ruíz / Moya, Patricia / Cabañas, Marina Tortosa / Estrada, Paula / Prado, Francisco Javier / Castañeda, Santos /

Blanco, Ricardo

Rheumatology (Oxford, England)

2024

Abstract: Objective: To determine the prevalence and predictive factors of visual manifestations in a large registry of patients with GCA.: Methods: ARTESER is a large Spanish multicentre registry supported by the Spanish Society of Rheumatology. It includes ... ...

Abstract	Objective: To determine the prevalence and predictive factors of visual manifestations in a large registry of patients with GCA. Methods: ARTESER is a large Spanish multicentre registry supported by the Spanish Society of Rheumatology. It includes patients with GCA from across the entire country diagnosed between June 2013 and March 2019. The variables collected at diagnosis were demographics, clinical manifestations (including all visual manifestations), laboratory, temporal artery biopsy, and imaging findings (ultrasound, FDG-PET/CT, MRI angiography, CT angiography). Patients with and without visual involvement were compared in a bivariate analysis. Multivariate logistic regression was performed to determine potential predictive factors of visual manifestations. Results: The study population comprised 1636 GCA patients, of whom 599 (36.6%) presented visual manifestations. Anterior ischemic optic neuropathy was the most frequent (n = 274 of 599; 45.7%) ocular complication. The independent predictors that increased the risk (OR; 95% confidence interval) of visual involvement were older age (1.027; 1.009-1.045) and jaw claudication (1.724; 1.325-2.243). The variables associated with a reduced risk were polymyalgia rheumatica (0.541; 0.414-0.708), fever (0.373; 0.264-0.527), longer symptom duration (0.946; 0.909-0.985), and higher erythrocyte sedimentation rate (ESR) (0.992; 0.988-0.997), common features of patients with large vessel-GCA. Conclusion: One-third of GCA patients present visual manifestations at diagnosis. Older age and jaw claudication are independent predictors of visual manifestations, whereas polymyalgia rheumatica, fever, longer symptom duration, and high ESR reduce the risk of visual involvement.
Language	English
Publishing date	2024-01-20
Publishing country	England
Document type	Journal Article
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keae042
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalence and clinical impact of systemic autoimmune rheumatic disease in patients with silicosis.

Blanco-Pérez, José Jesús / Arnalich-Montiel, Victoria / Salgado-Barreira, Ángel / Alvarez-Moure, María Angel / Caldera-Díaz, Adriana Carolina / Melero-Gonzalez, Rafael / Pallarés-Sanmartín, Abel / Fernandez-Villar, Alberto / González-Barcala, Francisco Javier

Archivos de bronconeumologia

2021 Volume 57, Issue 9, Page(s) 571–576

Abstract: Background: Silicosis is associated with an increased risk of developing systemic autoimmune rheumatic disease (SARD). The prognostic implications of this association are poorly characterized. The aim of this study was to determine the prevalence of ... ...

Abstract	Background: Silicosis is associated with an increased risk of developing systemic autoimmune rheumatic disease (SARD). The prognostic implications of this association are poorly characterized. The aim of this study was to determine the prevalence of SARD and autoimmune markers in a cohort of patients with exposure to silica and assess their impact on prognosis. Method: We performed a prospective observational study of all patients attending the dedicated silicosis clinic of our pulmonology unit between 2009 and December 2017. Diagnosis was confirmed by a rheumatologist according to Spanish Rheumatology Society criteria. Autoimmune markers, pulmonary function tests, radiological progression, visits to the emergency department and primary care center, and hospital admissions for respiratory causes, and mortality were analyzed. Results: Overall, 489 cases of silicosis and 95 cases of exposure were studied. In total, 54 (11.0%) patients with silicosis had SARD: 12 (2.4%) rheumatoid arthritis, 10 (2.0%) systemic lupus erythematosus, 10 (2.0%) systemic sclerosis, 3 (0.6%) Sjögren syndrome, 2 (0.4%) vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA +), 6 (1.2%) psoriatic arthritis, 3 (0.6%) ankylosing spondylitis, and 8 (1.6%) other autoimmune diseases with no special features. The patients with SARD visited the emergency room more often (63.0% vs. 42.5%; p = 0.004), and progressed more rapidly (22.2 vs. 11.7%; p = 0.030). Conclusions: The presence of systemic rheumatic autoimmune diseases involves radiological progression and a higher clinical impact.
MeSH term(s)	Autoimmune Diseases/epidemiology ; Humans ; Lupus Erythematosus, Systemic/complications ; Prevalence ; Rheumatic Diseases/diagnosis ; Rheumatic Diseases/epidemiology ; Silicosis/complications ; Silicosis/diagnostic imaging ; Silicosis/epidemiology
Language	English
Publishing date	2021-07-17
Publishing country	Spain
Document type	Journal Article ; Observational Study
ZDB-ID	733126-5
ISSN	1579-2129 ; 0300-2896
ISSN (online)	1579-2129
ISSN	0300-2896
DOI	10.1016/j.arbr.2021.06.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Biological therapy safety in chronic inflammatory arthropathy patients.

Martínez-López-de-Castro, Noemi / Álvarez-Payero, Miriam / Samartín-Ucha, Marisol / Martín-Vila, Alicia / Piñeiro-Corrales, Guadalupe / Rodríguez-Rodríguez, María / Maceiras-Pan, Francisco José / Melero-González, Rafael Benito / Pego-Reigosa, Jose María

European journal of rheumatology

2020 Volume 7, Issue 2, Page(s) 53–59

Abstract: Objective: The marketing of biological therapies transformed the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. But there is still concern about patient safety and management in daily clinical practice. The aim of ... ...

Abstract	Objective: The marketing of biological therapies transformed the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. But there is still concern about patient safety and management in daily clinical practice. The aim of this study was to estimate risk factors of the adverse effects in a cohort of Spanish patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods: A single institution, descriptive, retrospective, cohort study was developed from January 2009 to December 2016. Patients diagnosed with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis on biological therapies were included. Undesirable events affecting patients during biological therapy, their clinical implications and the use of health resources related to adverse effects were collected. Results: Three hundred and sixty-two patients corresponding to 478 biological therapy lines were analysed. It implied 1192 years of monitoring. There were 57 adverse effects per 100 biological patient-years and 4.8 serious adverse effects per 100 biological patient-years. The only significant factor for a likely serious adverse effect was having a Charlson Index ≥10, OR of 6.2 (CI 95%: 3.4-11.1, p<0.001). Around 15 % of patients with adverse effects were admitted to hospital and 25% received attention at the Emergency Department. Conclusion: Over half of the patients with arthropathies on biological therapy can suffer adverse effect during treatment but only 8.5% of these effects are serious. Special vigilance must be paid to patients with a higher number of comorbidities because they are more likely to experience serious adverse effects.
Language	English
Publishing date	2020-01-02
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2873727-1
ISSN	2148-4279 ; 2147-9720
ISSN (online)	2148-4279
ISSN	2147-9720
DOI	10.5152/eurjrheum.2019.19123
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prevalence and Clinical Impact of Systemic Autoimmune Rheumatic Disease in Patients with Silicosis.

Blanco Pérez, José Jesús / Arnalich Montiel, Victoria / Salgado-Barreira, Ángel / Alvarez Moure, María Angel / Caldera Díaz, Adriana Carolina / Melero Gonzalez, Rafael / Pallarés Sanmartín, Abel / Fernandez Villar, Alberto / González Barcala, Francisco Javier

Archivos de bronconeumologia

2020

Title translation	Prevalencia e impacto clínico de las enfermedades reumatológicas autoinmunitarias sistémicas en pacientes con silicosis.
Abstract	Background: Silicosis is associated with an increased risk of developing systemic autoimmune rheumatic disease (SARD). The prognostic implications of this association are poorly characterized. The aim of this study was to determine the prevalence of SARD and autoimmune markers in a cohort of patients with exposure to silica and assess their impact on prognosis. Method: We performed a prospective observational study of all patients attending the dedicated silicosis clinic of our pulmonology unit between 2009 and December 2017. Diagnosis was confirmed by a rheumatologist according to Spanish Rheumatology Society criteria. Autoimmune markers, pulmonary function tests, radiological progression, visits to the emergency department and primary care center, and hospital admissions for respiratory causes, and mortality were analyzed. Results: Overall, 489 cases of silicosis and 95 cases of exposure were studied. In total, 54 (11.0%) patients with silicosis had SARD: 12 (2.4%) rheumatoid arthritis, 10 (2.0%) systemic lupus erythematosus, 10 (2.0%) systemic sclerosis, 3 (0.6%) Sjögren syndrome, 2 (0.4%) vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA +), 6 (1.2%) psoriatic arthritis, 3 (0.6%) ankylosing spondylitis, and 8 (1.6%) other autoimmune diseases with no special features. The patients with SARD visited the emergency room more often (63.0 vs. 42.5%; p = 0.004), and progressed more rapidly (22.2 vs. 11.7%; p = 0.030). Conclusions: The presence of systemic rheumatic autoimmune diseases involves radiological progression and a higher clinical impact.
Language	Spanish
Publishing date	2020-05-31
Publishing country	Spain
Document type	Journal Article
ZDB-ID	2591346-3
ISSN	2173-5751 ; 2173-5751
ISSN (online)	2173-5751
ISSN	2173-5751
DOI	10.1016/j.arbres.2020.04.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Biological therapy safety in chronic inflammatory arthropathy patients.

European journal of rheumatology

2020 , Page(s) 1–7

Abstract	Objective: The marketing of biological therapies transformed the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. But there is still concern about patient safety and management in daily clinical practice. The aim of this study was to estimate risk factors of the adverse effects in a cohort of Spanish patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods: A single institution, descriptive, retrospective, cohort study was developed from January 2009 to December 2016. Patients diagnosed with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis on biological therapies were included. Undesirable events affecting patients during biological therapy, their clinical implications and the use of health resources related to adverse effects were collected. Results: Three hundred and sixty-two patients corresponding to 478 biological therapy lines were analysed. It implied 1192 years of monitoring. There were 57 adverse effects per 100 biological patient- years and 4.8 serious adverse effects per 100 biological patient-years. The only significant factor for a likely serious adverse effect was having a Charlson Index ≥10, OR of 6.2 (CI 95%: 3.4-11.1, p<0.001). Around 15 % of patients with adverse effects were admitted to hospital and 25% received attention at the Emergency Department. Conclusion: Over half of the patients with arthropathies on biological therapy can suffer adverse effect during treatment but only 8.5% of these effects are serious. Special vigilance must be paid to patients with a higher number of comorbidities because they are more likely to experience serious adverse effects.
Language	English
Publishing date	2020-01-02
Publishing country	Turkey
Document type	Journal Article
ZDB-ID	2873727-1
ISSN	2148-4279 ; 2147-9720
ISSN (online)	2148-4279
ISSN	2147-9720
DOI	10.5152/eurjrheum.2019.19123
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Adherence to biological therapies in patients with chronic inflammatory arthropathies.

Martínez-López de Castro, Noemí / Álvarez-Payero, Miriam / Samartín-Ucha, Marisol / Martín-Vila, Alicia / Piñeiro-Corrales, Guadalupe / Pego Reigosa, José María / Rodríguez-Rodríguez, María / Melero-González, Rafael Benito / Maceiras-Pan, Francisco José

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

2019 Volume 43, Issue 4, Page(s) 134–139

Abstract: Introduction: The aims of the study were to quantify adherence, determine the factors that can predict adherence and identify the consequences of poorer adherence in patients with chronic inflammatory arthropathies treated with biological therapies in ...

Title translation	Adherencia a las terapias biológicas en pacientes con artropatías inflamatorias crónicas.
Abstract	Introduction: The aims of the study were to quantify adherence, determine the factors that can predict adherence and identify the consequences of poorer adherence in patients with chronic inflammatory arthropathies treated with biological therapies in daily clinical practice. Method: A descriptive, observational and retrospective study was carried out. Patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis who started a biologic therapy between 1 January 2009 and 31 December 2016 were included. Variables related to socioeconomic status, the disease, the biological therapy and hospital resources were included. Adherence was calculated by using the medication possession ratio. Results: Three hundred and sixty-two patients and 423 lines of biological therapy were included. Mean age ± standard deviation was 50.3 ± 13.9 years, and 228 (53.9%) were women. The percentage of adherent patients was 187 out of 216 (87%) in rheumatoid arthritis, 91 out of 107 (85%) in ankylosing spondylitis and 84 out of 100 (84%) in psoriatic arthritis. Greater adherence was associated with more frequent visits to the pharmacy service (odds ratio 1.2, 95% confidence interval: 1.1-1.3 [p = 0.001]) and poorer adherence with a failure to attend scheduled appointments at the rheumatology clinic (odds ratio 0.2, 95% confidence interval: 0.1-0.9 [p = 0.030]). There were no differences between adherent and non-adherent patients in terms of the number of hospital resources used. Conclusions: There are no differences in adherence to biological therapies among patients with chronic inflammatory arthropathies. Adherence correlates with attendance at outpatient appointments, but this does not imply an increase in the use of hospital resources.
MeSH term(s)	Adult ; Aged ; Antirheumatic Agents/therapeutic use ; Arthritis/therapy ; Arthritis, Psoriatic/therapy ; Arthritis, Rheumatoid/therapy ; Biological Therapy/statistics & numerical data ; Chronic Disease ; Female ; Hospitals/statistics & numerical data ; Humans ; Inflammation/therapy ; Male ; Middle Aged ; Patient Compliance/statistics & numerical data ; Retrospective Studies ; Social Class ; Spondylitis, Ankylosing/therapy
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2019-07-01
Publishing country	Spain
Document type	Journal Article ; Observational Study
ZDB-ID	1122680-8
ISSN	2171-8695 ; 1130-6343
ISSN (online)	2171-8695
ISSN	1130-6343
DOI	10.7399/fh.11183
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study.

Samartín-Ucha, Marisol / Pego-Reigosa, Jose Maria / Álvarez-Payero, Miriam / Martin-Vila, Alicia / Pineiro-Corrales, Guadalupe / Rodriguez-Rodriguez, Maria / Melero-Gonzalez, Rafael Benito / Maceiras-Pan, Francisco / Martinez-Reglero, Cristina / Mrtinez-Lopez de Castro, Noemi

European journal of hospital pharmacy : science and practice

2020 Volume 28, Issue Suppl 2, Page(s) e47–e50

Abstract: Objectives: Medication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension ...

Abstract	Objectives: Medication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropathies: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods: Single institution, descriptive, retrospective cohort study. Adult patients with chronic inflammatory arthropathies on BT between January 2009 and December 2016 were included. Persistence to BT was compared considering the type of pathology and treatment. The Kaplan-Meier test was used to analyse medication persistanence and factors associated with it. An analysis of reasons for therapy discontinuation was performed. Results: Three hundred and sixty-two patients were included in the study, which comprised 478 BT lines. For all patients, the 12-month persistence rate was 71.3% (341 out of 478). At the end of the study, 45.2% of the patients continued on their initial BT. Median treatment persistence was 1489 days (CI 95% 1195 to 1783). Longer BT persistence was associated with naïve BT patients: 1945 days (95% CI 1523 to 2367; P<0.001) and ankylosing spondylitis diagnosis: 2402 days (95% CI 1604 to 3200; P=0.014). The most frequent causes of treatment discontinuation were therapeutic failure (47.6%) and adverse drug events (28.2%). Conclusions: We found good long-term persistence in patients with chronic inflammatory arthropathies treated with BT. Patients with rheumatoid arthritis had significantly shorter persistence compared with those with ankylosing spondylitis and psoriatic arthritis. Naïve BT was associated with longer persistence. Therapeutic failure was the main cause of BT withdrawal.
MeSH term(s)	Adult ; Antirheumatic Agents/adverse effects ; Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/drug therapy ; Arthritis, Psoriatic/epidemiology ; Biological Therapy ; Humans ; Medication Adherence ; Retrospective Studies
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2020-05-13
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2650179-X
ISSN	2047-9964 ; 2047-9956
ISSN (online)	2047-9964
ISSN	2047-9956
DOI	10.1136/ejhpharm-2019-002133
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study.

Martínez-López-de-Castro, Noemi / Álvarez-Payero, Miriam / Samartín-Ucha, Marisol / Martínez-Reglero, Cristina / Martín-Vila, Alicia / Rodríguez-Rodríguez, María / Piñeiro-Corrales, Guadalupe / Maceiras-Pan, José Francisco / Melero-González, Rafael Benito / Pego-Reigosa, Jose María

Clinical and experimental rheumatology

2020 Volume 39, Issue 4, Page(s) 736–745

Abstract: Objectives: The aim of the study was to assess the direct costs for the Spanish Health System of patients with chronic inflammatory arthropathies treated with biological therapies in daily clinical practice and to establish possible factors associated ... ...

Abstract	Objectives: The aim of the study was to assess the direct costs for the Spanish Health System of patients with chronic inflammatory arthropathies treated with biological therapies in daily clinical practice and to establish possible factors associated with lower costs. Methods: A descriptive, observational and retrospective study was conducted. Patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis who started a biological therapy between 1 January 2009 and 31 December 2016 were included. Variables related to socioeconomic status, disease and biological therapy were included. The annual cost of biological treatment and other direct medical costs were calculated for each disease. The analysis of costs was based on the National Health Service perspective. The time horizon comprised the 8-year long study period. Results: A total of 422 biological therapy lines were analysed. The annual biological therapy cost per patient was €12,494±3,865 for rheumatoid arthritis, €11,248±2,763 for ankylosing spondylitis and €12,263±35,155 for psoriatic arthritis (p=0.008). The cost of biological therapies entailed about 80% of the total cost of these diseases. Hospital admission was a factor which contributed to an increasing cost in all these conditions. A longer duration of the biological therapy was associated with lower cost in all the diseases. Conclusions: The cost of ankylosing spondylitis is lower than that of rheumatoid arthritis and psoriatic arthritis. The biological therapy is the factor with the highest impact on the overall cost of these diseases. Preventing hospital admissions and a higher persistence to the biological therapy can contribute to lower costs for the system.
MeSH term(s)	Antirheumatic Agents/adverse effects ; Arthritis, Psoriatic/drug therapy ; Biological Therapy ; Humans ; Retrospective Studies ; Spondylitis, Ankylosing/drug therapy ; State Medicine
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2020-09-03
Publishing country	Italy
Document type	Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
DOI	10.55563/clinexprheumatol/x1h3xi
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.

Galíndez-Agirregoikoa, Eva / Prieto-Peña, Diana / Martín-Varillas, José Luis / Joven, Beatriz / Rusinovich, Olga / Melero-González, Rafael B / Ortiz-Sanjuan, Francisco / Almodóvar, Raquel / Alegre-Sancho, Juan José / Martínez, Ángels / Sellas-Fernández, Agustí / Méndez, Lara / García-Vicuña, Rosario / Atienza-Mateo, Belén / Gorostiza, Iñigo / González-Gay, Miguel Ángel / Blanco, Ricardo

The Journal of rheumatology

2021 Volume 48, Issue 10, Page(s) 1552–1558

Abstract: Objective: Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-α in randomized controlled trials (RCTs). Our aim was to assess ... ...

Abstract	Objective: Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-α in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. Methods: This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. Results: There were 87 patients (28 women/59 men), with a mean age of 52.8 ± 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 ± 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, Conclusion: Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.
MeSH term(s)	Adult ; Arthritis, Psoriatic/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Piperidines ; Pyrimidines/therapeutic use ; Pyrroles/therapeutic use ; Treatment Outcome
Chemical Substances	Piperidines ; Pyrimidines ; Pyrroles ; tofacitinib (87LA6FU830)
Language	English
Publishing date	2021-04-01
Publishing country	Canada
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.201204
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito